Atea Pharmaceuticals (AVIR) EPS (Weighted Average and Diluted): 2019-2024
Historic EPS (Weighted Average and Diluted) for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to -$2.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted) fell 131.06% to -$0.41 in Q4 2022 from the same period last year, while for Dec 2022 it was -$1.40, marking a year-over-year decrease of 204.48%. This contributed to the annual value of -$2 for FY2024, which is 22.70% down from last year.
- Atea Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$2 in FY2024, which was down 22.70% from -$1.63 recorded in FY2023.
- Atea Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $1.37 for FY2021, and its period low was -$2 during FY2024.
- In the last 3 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$1.63 in 2023 and averaged -$1.67.
- In the last 5 years, Atea Pharmaceuticals' EPS (Weighted Average and Diluted) soared by 368.63% in 2021 and then plummeted by 201.46% in 2022.
- Yearly analysis of 5 years shows Atea Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.51 in 2020, then soared by 368.63% to $1.37 in 2021, then slumped by 201.46% to -$1.39 in 2022, then decreased by 17.27% to -$1.63 in 2023, then dropped by 22.70% to -$2 in 2024.